266 related articles for article (PubMed ID: 22562783)
1. Safety and efficacy of moxifloxacin-dexamethasone eyedrops as treatment for bacterial ocular infection associated with bacterial blepharitis.
Belfort R; Gabriel L; Martins Bispo PJ; Muccioli C; Zacharias Serapicos PC; Clark L; Bell B; Bartell J; Stroman DW; Höfling-Lima AL
Adv Ther; 2012 May; 29(5):416-26. PubMed ID: 22562783
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and tolerability of a combined moxifloxacin/dexamethasone formulation for topical prophylaxis and reduction of inflammation in phacoemulsification: a comparative, double masked clinical trial.
Freitas LL; Soriano E; Muccioli C; Höfling-Lima AL; Belfort R
Curr Med Res Opin; 2007 Dec; 23(12):3123-30. PubMed ID: 17980093
[TBL] [Abstract][Full Text] [Related]
3. Clinical efficacy of moxifloxacin in the treatment of bacterial keratitis: a randomized clinical trial.
Constantinou M; Daniell M; Snibson GR; Vu HT; Taylor HR
Ophthalmology; 2007 Sep; 114(9):1622-9. PubMed ID: 17822972
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of besifloxacin ophthalmic suspension 0.6% compared with moxifloxacin ophthalmic solution 0.5% for treating bacterial conjunctivitis.
McDonald MB; Protzko EE; Brunner LS; Morris TW; Haas W; Paterno MR; Comstock TL; Usner DW
Ophthalmology; 2009 Sep; 116(9):1615-1623.e1. PubMed ID: 19643483
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of clinical efficacy and safety of tobramycin/dexamethasone ophthalmic suspension 0.3%/0.05% compared to azithromycin ophthalmic solution 1% in the treatment of moderate to severe acute blepharitis/blepharoconjunctivitis.
Torkildsen GL; Cockrum P; Meier E; Hammonds WM; Silverstein B; Silverstein S
Curr Med Res Opin; 2011 Jan; 27(1):171-8. PubMed ID: 21138337
[TBL] [Abstract][Full Text] [Related]
6. Moxifloxacin five-day therapy versus placebo in acute bacterial rhinosinusitis.
Hadley JA; Mösges R; Desrosiers M; Haverstock D; van Veenhuyzen D; Herman-Gnjidic Z
Laryngoscope; 2010 May; 120(5):1057-62. PubMed ID: 20422704
[TBL] [Abstract][Full Text] [Related]
7. Microbiological efficacy of a new ophthalmic formulation of moxifloxacin dosed twice-daily for bacterial conjunctivitis.
Tauber S; Cupp G; Garber R; Bartell J; Vohra F; Stroman D
Adv Ther; 2011 Jul; 28(7):566-74. PubMed ID: 21681652
[TBL] [Abstract][Full Text] [Related]
8. Effects of intravitreal moxifloxacin and dexamethasone in experimental Staphylococcus aureus endophthalmitis.
Ermis SS; Cetinkaya Z; Kiyici H; Inan UU; Ozturk F
Curr Eye Res; 2007 Apr; 32(4):337-44. PubMed ID: 17453955
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of moxifloxacin 0.5% in treatment of nonperforated bacterial corneal ulcers: a randomized controlled trial.
Sharma N; Goel M; Bansal S; Agarwal P; Titiyal JS; Upadhyaya AD; Vajpayee RB
Ophthalmology; 2013 Jun; 120(6):1173-8. PubMed ID: 23415776
[TBL] [Abstract][Full Text] [Related]
10. Antimicrobial efficacy of prophylactic gatifloxacin 0.3% and moxifloxacin 0.5% in patients undergoing phacoemulsification surgery.
Bucci FA; Amico LM; Evans RE
Eye Contact Lens; 2008 Jan; 34(1):39-42. PubMed ID: 18180682
[TBL] [Abstract][Full Text] [Related]
11. Clinical safety of moxifloxacin ophthalmic solution 0.5% (VIGAMOX) in pediatric and nonpediatric patients with bacterial conjunctivitis.
Silver LH; Woodside AM; Montgomery DB
Surv Ophthalmol; 2005 Nov; 50 Suppl 1():S55-63. PubMed ID: 16257311
[TBL] [Abstract][Full Text] [Related]
12. Treatment of experimental Bacillus cereus endophthalmitis using intravitreal moxifloxacin with or without dexamethasone.
Sakalar YB; Ozekinci S; Celen MK
J Ocul Pharmacol Ther; 2011 Dec; 27(6):593-8. PubMed ID: 21834669
[TBL] [Abstract][Full Text] [Related]
13. A phase III clinical trial of 0.5% levofloxacin ophthalmic solution versus 0.3% ofloxacin ophthalmic solution for the treatment of bacterial conjunctivitis.
Schwab IR; Friedlaender M; McCulley J; Lichtenstein SJ; Moran CT;
Ophthalmology; 2003 Mar; 110(3):457-65. PubMed ID: 12623805
[TBL] [Abstract][Full Text] [Related]
14. Dexamethasone-netilmicin: a new ophthalmic steroid-antibiotic combination. Efficacy and safety after cataract surgery.
Russo S; Papa V; Di Bella A; Favero A; Radulescu C; Gafencu O; Carstocea B; Milazzo G
Eye (Lond); 2007 Jan; 21(1):58-64. PubMed ID: 16273088
[TBL] [Abstract][Full Text] [Related]
15. Prophylactic effect of intravenous moxifloxacin in a rabbit model of Staphylococcus epidermidis endophthalmitis.
Kim JY; Kim SY
Invest Ophthalmol Vis Sci; 2011 Mar; 52(3):1742-7. PubMed ID: 21169530
[TBL] [Abstract][Full Text] [Related]
16. Oral antibiotics for fever in low-risk neutropenic patients with cancer: a double-blind, randomized, multicenter trial comparing single daily moxifloxacin with twice daily ciprofloxacin plus amoxicillin/clavulanic acid combination therapy--EORTC infectious diseases group trial XV.
Kern WV; Marchetti O; Drgona L; Akan H; Aoun M; Akova M; de Bock R; Paesmans M; Viscoli C; Calandra T
J Clin Oncol; 2013 Mar; 31(9):1149-56. PubMed ID: 23358983
[TBL] [Abstract][Full Text] [Related]
17. Randomized clinical study for comparative evaluation of fourth-generation fluoroquinolones with the combination of fortified antibiotics in the treatment of bacterial corneal ulcers.
Shah VM; Tandon R; Satpathy G; Nayak N; Chawla B; Agarwal T; Sharma N; Titiyal JS; Vajpayee RB
Cornea; 2010 Jul; 29(7):751-7. PubMed ID: 20489580
[TBL] [Abstract][Full Text] [Related]
18. Safety of intracameral moxifloxacin for prophylaxis of endophthalmitis after cataract surgery.
Arbisser LB
J Cataract Refract Surg; 2008 Jul; 34(7):1114-20. PubMed ID: 18571078
[TBL] [Abstract][Full Text] [Related]
19. Evidence-based review of moxifloxacin.
O'Brien TP
Int Ophthalmol Clin; 2006; 46(4):61-72. PubMed ID: 17060792
[No Abstract] [Full Text] [Related]
20. Efficacy and safety of besifloxacin ophthalmic suspension 0.6% in children and adolescents with bacterial conjunctivitis: a post hoc, subgroup analysis of three randomized, double-masked, parallel-group, multicenter clinical trials.
Comstock TL; Paterno MR; Usner DW; Pichichero ME
Paediatr Drugs; 2010 Apr; 12(2):105-12. PubMed ID: 20218747
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
